DOCSLIB.ORG

The Haunting of Medical Literature

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Haunting of Medical Literature Pharmacy and Wellness Review Volume 2 Issue 1 Article 1 March 2011 The Haunting of Medical Literature Brieann Miller Ohio Northern University Tana Peterman Ohio Northern University Follow this and additional works at: https://digitalcommons.onu.edu/paw_review Part of the Other Pharmacy and Pharmaceutical Sciences Commons This Editorial is brought to you for free and open access by the ONU Journals and Publications at DigitalCommons@ONU. It has been accepted for inclusion in Pharmacy and Wellness Review by an authorized editor of DigitalCommons@ONU. For more information, please contact [email protected]. TH» PllARMACY A.No WELLNESS REv1E~' Editorial The Haunting of Medical Literature Bneann Miller, hfth-year i:tiarmacy student from Fairfield, Ohio, Tana Peterman, fifth-year pharmacy student from Jacksonville, N.C. able contributions to a paper from authorship is one of the Abstract most significant aspects of ghostwntmg. More importantly, with Ghostwriting, or using the names of academic resea rchers to the title of author comes a responsibility to ensure that the validate studies commissioned by pharmaceutical companies, has paper's content, intent and findings are based on the results of become a growing concern within medical literature. Omission from the study and scientific principle and not skewed by financial authorship of the names of individuals making considerable conllibu­ or political gain.5 Authors lis t disclosure statements to inform tions to a paper is one of the most significant aspects of ghostwrit­ the reader of existing co nflicts of interest; however, the term ing. Policy prohibiting medical ghostwriting is lacking, and it is nearly "conftlct of interest' 1s difficult to define. These conflicts typically impossible to prevent the practice without strict and thorough guide­ include employment, grants and other financial support, bur the lines. More strict guidelines banning ghostwriting, denying govern­ lines become blurred when referring to patent nghts. per- ment funds to organ12at1ons without such policies, and development sonal relationships or political ties. When the true authors are of databases to track offending authors and organizations could excluded from publications, rhey cannot be held responsible tor decrease the impact of ghostwnting in medical literature. the integrity of their work. Polley proh1b1ting medical ghostwntmg 1s lacking. In an evalu­ Background ation of 50 of the top academic medical centers m the United Clinical evidence has come to be revered as the standard of truth in States, 52 percent had no published policy regarding author­ medical practX:e. Pharmacists turn to clinical literature to make sound ship or ghostwritmg.1 Without a policy in pace, It IS nearly recommendations for patient drug therapy. It 1s often ass urned that impossible to stop this type of unethical misconduct While the the integrity and validity of a published paper is ensured by referring to responsibility of honesty and disclosure lies with the author, literature in esteemed, peer-reviewed journals. However, ethical con­ there are few tools available for editors to police authorship va­ siderations and conflicts of int'lrest in authorship are slipping through lidity 5 A mere 8.8 percent of pumals have a policy for verifying quality assurance systems employed by these pumals and threatening author claims and conflicts of interest. 6 the foundation of medicine. Ghostwriting, or using the names of aca­ demrc researchers to validate studies comm1ss1oned by pharmaceuncal A case of Ghostwriting 1 companies, has become a growing concern within medical lrterarure. An example of ghostwriting that is thought to significantly Also concerning may be the use of publication planning, a form of impact the medical literature wa s when a oharmaceutJcal systematically populating mec1cal literature on the corporate scale. manufacturer attempted to prove that their drug could be used Publication planning 1s conducted by a team of people employed by a as an antidepressant in adolescents.7 This study's results were pharmaceutical manufacturer in an attempt to control every possible published 1n the Journal of the American Academy of Child aspect of public information available about a drug of interest.2 and Adolescent Psychiatry and listed 22 authors. The idea for PublicatJon plans include strategies for conducting explicit trials that the study came from the primary author and was accepted and yield desired results combined with the carefully timed release of conducted by the pharmaceutical manufacturer However, the information to specific target audiences. In some cases, the planning result of this study and similar studies showed no efficacy for team may be more responsible for manuscripts submitted to medical the drug in adolescents compared to placebo. The manufactur­ pumals than the respected author(s) appearing on the page. er worried that the lack of efficacy in pediatrics would possibly make the medical community question the efficacy of the drug Contributing Factors in general. Therefore, the manufacturer decided only to publish The first factor conrributing to medical ghostwriting is the definition of the positive findings from the study. A medical publishing com­ authorship. The correct protocol for listing authors 1s complicated by pany was hired to draft the positive information and prepare it histoncal methods of listing authors alphabetically or l1Sting the head for publicat10n. of department as lead author as a sign of respect.3 Currently, the International Committee Medical Journal Editors defines author­ ot A synopsis of the clinica l report was provided to the ghostwnter ship as fulfilling allot the following criteria for authorship suootantial 1n the medical publlshing group who used this shortened report contnbutJon to conception anc design , acquisition of data, or analys1S to wnte the first draft of the manuscnpt. The ghostwnter also and 1merpretat10n of data, drafting the article and/or revising 1t cntically was found to have contributed to the article by developing and for important intellectual content, and final approval of the versio n to implementing a publication plan, responding to peer-reviews, be published.• Om1Ssion of the names of ind1v1duals making consider- and providing the primary author with drafts and cover letters. 1 THE P HARMACY AND W EL LNESS Re view Volume two. Issue one March 2011 The Haunting of Medical Literature Editorial Research looking into the communicatio n be tween the listed authors and Discussion employees at the medical publishing compa ny showed that many of the Ghostwriting will not be stopped until all levels of medical publishing 22 listed authors had little to no involvement with the article. The ghost­ commit to higher sta ndards for literary ethics. PractitJoners have a right wnter was actually the pnmary writer of the article drafts, even though to be informed of these conflicts of interest in literature so they can not listed as such. Also, 1t was shown that the second and third authors make their own decisions about the clinical validity of the evidence they made only minor edits to the articlg throughout the process. Many of the are reading . Ghostwriting and publication planmng allow publication of authors were shown to have only made small edits to one of the drans. biased or incomplete 1ntormat1on that may be harmful to patients who having only assisted in running the study, or having made no recogniz­ begin therapy with a medication with side effects and risks that are not able contribution at all.7 fully disclosed. Many pa tients now may be suffering from severe adverse effects of med ications because the dangers we re not known and the A ma pr issue with the first draft was that there were noticeable dif­ treatment was marketed as be ing safe and effective. Ghostwriting is an ferences between it and the final clinical report, even though this was emerging problem in medical writing that not only has ethical implica­ the source used to write the first draft. In the clinical report it is stated tions, but also affects patients and their wellbeing. The quality of medical that only two primary outcomes were measured. In the first draft, eight care provided to patients is only as strong as the integrity of the literature primary outcomes were mentio ned: four of these outcomes showed that backs it. increased efficacy of the drug over placebo, wh ich contradicts the findings of the srudy. Also, the line between the primary and secondary Citations outcomes was blurred. After peer review, the article was edited again to 1. Lacasse JR, Leo J. Ghos twnting at elite academic medical centers include only the original two pnmary outcomes , but the information was in the united states. PLoS 20 10; 7(2). 1-4. presented in such a way that one of the outcomes appeared to be pos1- 2. Sismondo S. Ghosts in the machine. publication planning in the t1 ve and reinforced the Idea of efficacy for the drug. The side effects of medical sciences. Soc Stud Sci 2009, 39(2) 171-198. the medication were inconsistent with the original report as well, and the 3. Melnick A. Cha nge and medical writing. AMWA 2009. 24(3): 139. seriousness of some listed side effects was not expressed. 7 4. International Committee of Medical Journal Editors. Ethical Consid­ eratrons in the Conduct and Reporti ng of Research: Authorship and The results of this study being published include many clinicians Contributorship. Available atwww.ic m~. org/ethical_1author.h tml. believing the drug to be an effective and highly tolerable medication Accessed Nov. 23 , 20 10. for adolescents. In 207 articles published since 2008, this study was 5. Roberts J. An author's guide to publication ethics: a review of mentioned and used as evidence that the drug is effective fo r use in emerging standards in biomedical j:Jumals. Headache 2009; 49: adolescents. Only 31 of these articles correctly presented the informa­ 578-589.
Load more

Recommended publications
  • Evaluation of Medical Literature and Journal Clubs
    4 Evaluation of Medical Literature and Journal Clubs Lindsay Davison, PharmD, and Jean Cunningham, PharmD, BCPS CASE H.G. is a pharmacy student on an internal medicine APPE rotation. At the end of the month, all students on the rotation are required to participate in the pharmacy’s journal club. H.G. remembers presenting a handful of journal clubs during pharmacy school, but he has never presented to a roomful of pharmacists before. Why It’s Essential Discussions about journal clubs and medical literature evaluation have been known to cause rapid heart rate, increased blood pressure, and a host of other unfortunate adverse events in otherwise healthy fi nal-year student pharmacists (please note: these data were derived from observational N of 1 studies). Alas, have no fear! This chapter is here to save you. You may wonder why medical literature evaluation and journal clubs are considered part of The Essentials. Medical literature is what creates the treatment guidelines we rely on as clinicians, and its evaluation is how we can be confi dent (or not so confi dent) in a publication’s fi ndings. Just as you would not drive a car through an intersection with your eyes shut while the passenger concluded that the coast was clear, you should not accept the author’s conclusions of a trial without evaluating the literature. Understandably, you may now be wondering how in the world pharmacists can fi nd the time to evaluate all of the medical literature that impacts their practice. The answer is that they do not. This is where journal clubs come in.
    [Show full text]
  • REVIEW ESSAY Situating the History of Medicine Within Chinese History
    REVIEW ESSAY Situating the History of Medicine within Chinese History Marta Hanson, John Hopkins University Andrew Schonebaum. Novel Medicine: Healing, Literature, and Popular Knowledge in Early Modern China. Seattle: University of Washington Press, 2016. 296 pp. $50 (cloth); $30 (paper). Hilary A. Smith. Forgotten Disease: Illnesses Transformed in Chinese Medicine. Stanford, CA: Stanford University Press, 2017. 248 pp. $85 (cloth); $25 (paper/e-book). The past ten years have seen the publication of more than seventy English-language monographs, edited books, translations, dictionaries, and even a three-volume catalogue, related to the history of medicine in China. Such substantive, varied, and often ground-breaking scholarship is finally starting to do justice to the complexity of the subject and the richness of the sources vis-à-vis the better known, and thus more widely taught, history of European and Anglo-American medicine from antiquity to the modern world. Collectively bringing the field of the history of medicine in China to a new level of synthesis, these works not only demonstrate how integral the history of medicine and public health is to Chinese history but also should help facilitate the integration of East Asian medical history into more broadly conceived global histories of medicine and public health. This major boon in publications on the medical history of China over the past decade also reveals the wide-ranging methods and diverse approaches scholars have chosen to frame, and thereby exert heuristic control over, what arguably has become newly visible as the contours of a vast, complex, and essential subject of not just Chinese but human history.
    [Show full text]
  • Annotated Bibliography of Journals for Educational Scholarship
    AAMC-Regional Groups on Educational Affairs (GEA) Medical Education Scholarship, Research and Evaluation Section Annotated Bibliography of Journals for Educational Scholarship Revised July 2019 Coordinated by: SGEA (Southern Group on Educational Affairs) in collaboration with NEGEA, WGEA and CGEA. Compiled by: Andrea Berry, MPA University of Central Florida College of Medicine Compiling Authors: Lisa Coplit, MD Frank H. Netter MD School of Medicine Alice Fornari, EdD, RD Hofstra North Shore-LIJ University School of Medicine Larrie Greenberg, MD George Washington University School of Medicine Keith Metzger, PhD Hofstra North Shore-LIJ University School of Medicine Susan Pasquale, PhD, MT-BC, NMT University of Massachusetts Medical School Janine Shapiro, MD University of Rochester Medical Center Laura Willett, MD, FACP Robert Wood Johnson Medical School Nagaswami Vasan, PhD UMDNJ-Robert Wood Johnson Medical School DR-ED E-list Librarian Coordinators Pamela Herring, MLIS, D-AHIP, Harriet F. Ginsburg Health Sciences Library, University of Central Florida College of Medicine Judy M. Spak, MLS, Harvey Cushing/John Hay Whitney Medical Library, Yale School of Medicine For questions/suggestions contact Andrea Berry at [email protected]. THANKS! Contents Academic Emergency Medicine 5 Academic Emergency Medicine Education & Training 5 Academic Medicine 6 Academic Pathology - Supports Open Access 7 Academic Pediatrics 7 Academic Psychiatry - Supports Open Access 8 Academic Radiology - Supports Open Access 9 Advances in Health Sciences Education
    [Show full text]
  • From Drug Literature Evaluation to Evidence-Based Medicine: Transforming the Focus of a First Year Pharmacy Curriculum
    Volume 7 | Number 2 Article 2 4-22-2016 From Drug Literature Evaluation to Evidence- Based Medicine: Transforming the Focus of a First Year Pharmacy Curriculum Shannon Reidt University of Minnesota College of Pharmacy, [email protected] Keri Hager University of Minnesota College of Pharmacy, [email protected] James Beattie University of Minnesota Medical School, [email protected] Amy Pittenger University of Minnesota College of Pharmacy, [email protected] Maureen Smith University of Minnesota College of Pharmacy, [email protected] See next page for additional authors Follow this and additional works at: http://pubs.lib.umn.edu/innovations Recommended Citation Reidt S, Hager K, Beattie J, et al. From Drug Literature Evaluation to Evidence-Based Medicine: Transforming the Focus of a First Year Pharmacy Curriculum. Inov Pharm. 2016;7(2): Article 2. http://pubs.lib.umn.edu/innovations/vol7/iss2/2 INNOVATIONS in pharmacy is published by the University of Minnesota Libraries Publishing. From Drug Literature Evaluation to Evidence-Based Medicine: Transforming the Focus of a First Year Pharmacy Curriculum Authors Shannon Reidt, Keri Hager, James Beattie, Amy Pittenger, Maureen Smith, and Kristin Janke This case study is available in INNOVATIONS in pharmacy: http://pubs.lib.umn.edu/innovations/vol7/iss2/2 Case Study Report EDUCATION From Drug Literature Evaluation to Evidence-Based Medicine: Transforming the Focus of a First Year Pharmacy Curriculum Shannon Reidt, PharmD, MPHa; Keri Hager, PharmD, BCACPa; James Beattie, MLISb*; Amy Pittenger, PharmD, PhDa; Maureen Smith, MEda; Kristin Janke, PhDa aUniversity of Minnesota College of Pharmacy; bUniversity of Minnesota Medical School *At the time of this work, James Beattie was associated with the University of Minnesota Biomedical Library Abstract This case study describes a longitudinal curricular sequence implemented to teach evidence-based medicine (EBM) skills.
    [Show full text]
  • Users' Guides to the Medical Literature
    THE MEDICAL LITERATURE Users’ Guides to the Medical Literature XIX. Applying Clinical Trial Results B. Guidelines for Determining Whether a Drug Is Exerting (More Than) a Class Effect Finlay A. McAlister, MD, FRCPC your patients with elevated choles- Herein, we define a drug class as those Andreas Laupacis, MD, MSc, FRCPC terol levels, but are uncertain which of drugs that share a similar structure and the statins on the market is best. You mechanism of action. Most classes of George A. Wells, MSc, PhD ask a general internist, cardiologist, and drugs include multiple compounds, and David L. Sackett, FRSC, MD, FRCP endocrinologist for their opinions, and because of their similar mechanisms of for the Evidence-Based Medicine each suggests a different statin, citing action, they are generally thought to con- Working Group different reasons. You contact pharma- fer similar pharmacologic effects and ceutical representatives to provide you clinical outcomes (class effects). This 3 OST CLASSES OF DRUGS IN- with evidence that their statins are bet- assumption is a key medical heuristic clude multiple com- ter than those of their competitors. Al- and underlies clinical practice guide- pounds. The opinions of though you use the JAMA series on Us- lines in which evidence from studies clinicians, manufactur- ers’ Guides to the Medical Literature to involving 1 or more drugs within a class Mers, and purchasers may differ as to assess the validity of published stud- is extrapolated to other drugs of the same whether a particular drug is more effi- ies, faced with a variety of competing class. For example, it is recommended cacious, safer, or more cost-effective claims, you realize that you need a that b-blockers be prescribed for survi- than others in its class.1 In this article, framework for grading the strength of vors of myocardial infarction or angio- we review the types of evidence com- these studies.
    [Show full text]
  • Users' Guides to the Medical Literature
    THE MEDICAL LITERATURE Users’ Guides to the Medical Literature XXV. Evidence-Based Medicine: Principles for Applying the Users’ Guides to Patient Care Gordon H. Guyatt, MD, MSc This series provides clinicians with strategies and tools to interpret and in- R. Brian Haynes, MD, PhD tegrate evidence from published research in their care of patients. The 2 key Roman Z. Jaeschke, MD, MSc principles for applying all the articles in this series to patient care relate to the value-laden nature of clinical decisions and to the hierarchy of evidence Deborah J. Cook, MD, MSc postulated by evidence-based medicine. Clinicians need to be able to dis- Lee Green, MD, MPH tinguish high from low quality in primary studies, systematic reviews, prac- C. David Naylor, MD, PhD tice guidelines, and other integrative research focused on management rec- ommendations. An evidence-based practitioner must also understand the Mark C. Wilson, MD, MPH patient’s circumstances or predicament; identify knowledge gaps and frame W. Scott Richardson, MD questions to fill those gaps; conduct an efficient literature search; critically for the Evidence-Based Medicine appraise the research evidence; and apply that evidence to patient care. How- Working Group ever, treatment judgments often reflect clinician or societal values concern- ing whether intervention benefits are worth the cost. Many unanswered ques- CLINICAL SCENARIO tions concerning how to elicit preferences and how to incorporate them in A senior resident, a junior attending, a clinical encounters constitute an enormously challenging frontier for evidence- senior attending, and an emeritus pro- based medicine. Time limitation remains the biggest obstacle to evidence- fessor were discussing evidence-based based practice but clinicians should seek evidence from as high in the ap- medicine (EBM) over lunch in the hos- propriate hierarchy of evidence as possible, and every clinical decision should pital cafeteria.
    [Show full text]
  • The Thorax in History 3. Beginning of the Middle Ages
    Thorax: first published as 10.1136/thx.33.3.295 on 1 June 1978. Downloaded from Thorax, 1978, 33, 295-306 The thorax in history 3. Beginning of the Middle Ages R. K. FRENCH From the Wellcome Unit for the History of Medicine, University of Cambridge The end of Hellenistic experiment and observation physicians and surgeons did not give the Alexandrians the importance that historical hind- When Galen died at the end of the second century, sight attributes to them, nor did they recognise anatomical and physiological research died with Galen as authoritative as Galen's and later ages him. We are effectively in the dark ages at once, believed him to be. To a certain extent this is for the continued, if precarious, political stability true of the East as of the West: Aretaeus of of the Roman Empire was no substitute for the Cappadocia in Asia Minor was contemporary with, loss of vigour of the Greek intellectual tradition. or slightly later than Galen, but does not mention Galen's works survived, were commented upon him. Fragments of anatomy and physiology that and summarised, but no new inquiry was under- can be gleaned from his surviving works on the taken. When Galen visited Rome, it was as far signs and causes of acute and chronic diseases3 west as anatomy and physiology came: Pergamon, come from a variety of sources, some of them Alexandria, and Ephesus were the inheritors of purely traditional. Indeed, in Aretaeus we see an intellectual climate that sustained anatomy in more clearly than in Galen's synthetic physiology any form other than that employed by the sur- a distinction between traditional, literary anatomy, http://thorax.bmj.com/ geons of the legions.
    [Show full text]
  • Can Avicenna Help Manage the Diabetes Epidemic in Central Asia? Mizhgona Sharofova Avicenna Tajik State Medical University
    City University of New York (CUNY) CUNY Academic Works Publications and Research Hostos Community College Winter 11-2017 Can Avicenna Help Manage the Diabetes Epidemic in Central Asia? Mizhgona Sharofova Avicenna Tajik State Medical University, Yusuf Nuraliev Avicenna Tajik State Medical University, Parviz Sukhrobov Institute of Avicenna’s Medicine and Pharmacology Shoista Sagdieva Academy of Sciences of the Republic of Tajikistan Vyacheslav Dushenkov CUNY Hostos Community College How does access to this work benefit ou?y Let us know! Follow this and additional works at: https://academicworks.cuny.edu/ho_pubs Part of the Alternative and Complementary Medicine Commons Recommended Citation Sharofova, M., Y. Nuraliev, P. Sukhrobov, S. Sagdieva and V. Dushenkov (2017). "Can Avicenna Help Manage the Diabetes Epidemic in Central Asia?" Central Asian Journal of Medical Sciences 3(3): 200-220. This Article is brought to you for free and open access by the Hostos Community College at CUNY Academic Works. It has been accepted for inclusion in Publications and Research by an authorized administrator of CUNY Academic Works. For more information, please contact [email protected]. Review Article Cent Asian J Med Sci. 2017 Nov;3(3):200-220 https://doi.org/10.24079/CAJMS.2017.11.002 Can Avicenna Help Manage the Diabetes Epidemic in Central Asia? Mizhgona Sharofova1,2,3, Yusuf Nuraliev1,2, Parviz Sukhrobov2, Shoista Sagdieva2,3, Vyacheslav Dushenkov4 1Central Research Laboratory, Avicenna Tajik State Medical University, Dushanbe, Tajikistan; 2Institute of Avicenna’s Medicine and Pharmacology, Dushanbe, Tajikistan; 3Center for Research in Innovative Technologies, the Academy of Sciences of the Republic of Tajikistan, Dushanbe, Tajikistan; 4Naturals Sciences Department, Eugenio María de Hostos Community College of the City University of New York, Bronx, New York, USA Submitted: July 27, 2017 Objectives: The fast-rising rate of diabetes incidents is a growing concern in Central Asian Revised: September 29, 2017 countries.
    [Show full text]
  • Randomized Clinical Trials
    15 Randomized clinical trials One pill makes you larger, and one pill makes you small. And the ones your mother gives you, don’t do anything at all. Grace Slick, The Jefferson Airplane: White Rabbit, from Surrealistic Pillow, 1967 Learning objectives In this chapter you will learn: ● the unique features of randomized clinical trials (RCTs) ● how to undertake critical interpretation of RCTs The randomized clinical trial (RCT) is the ultimate paradigm of clinical research. Many consider the RCT to be the most important medical development of the twentieth century, as their results are used to dictate clinical practice. Although these trails are often put on a pedestal, it is important to realize that as with all experiments, there may be flaws in the design, implementation, and interpretation of these trials. The competent reader of the medical literature should be able to evaluate the results of a clinical trial in the context of the potential biases introduced into the research experiment, and determine if it contains any fatal flaws Introduction The clinical trial is a relatively recent development in medical research. Prior to the 1950s, most research was based upon case series or uncontrolled observations. James Lind, a surgeon in the British Navy, can claim credit for performing the first recorded clinical trial. In 1747, aboard the ship Salisbury, he took 12 sailors with scurvy and divided them into six groups of two each. He made sure they were similar in every way except for the treatment they received for scurvy. Dr. Lind found that the two sailors who were given oranges and lemons got better while the other ten did not.
    [Show full text]
  • Evidence-Based Medicine (EBM): What Long-Term Care Providers Need to Know
    Evidence-Based Medicine (EBM): What Long-Term Care Providers Need to Know Huai Y. Cheng, MD, MPH KEYWORDS Evidence-based medicine Long-term care facility Nursing homes EBM Evidence-based medicine (EBM) has been exponentially disseminated to every field of medicine over past 2 decades.1–7 EBM is now a part of postgraduate competency through practice-based learning.8 However, its potential use in the long-term care setting was only recently appreciated in the literature.1,9,10 EBM may play an important role in reforming nursing homes and improving quality care.1–5,9,10 The simple search term “EBM,” limited to English and human in Medline, generated 49,304 citations, which narrowed to only 173 when “nursing homes” was added, indi- cating that EBP is not rare and is being implemented in long-term care. It has been a great effort that each article in this special issue presents evidence-based recommen- dations to long-term care providers to guide their daily practice. In contrast to the evidence-based approach to individual geriatric conditions addressed in the other arti- cles in this issue, this article briefly introduces the basic concept of EBM; addresses some potential benefits, harms, and challenges of its practice in a long-term care setting; and promotes its appropriate use among providers of long-term care. For those who already know the EBM basics and are interested in become experts, several textbooks on EBM are recommended.11–13 Attending an EBM workshop, such as one run by McMaster University,14 could also be helpful.
    [Show full text]
  • Contributions of Muslim Scholars Attributed to Other Scholars in Engineering and Medicine
    International Journal of Applied Science and Technology Vol. 7, No. 3, September 2017 Contributions of Muslim Scholars Attributed to Other Scholars in Engineering and Medicine Asfana Banu Abdi O. Shuriye Faculty of Engineering International Islamic University Malaysia P.O. Box 10, 50728 Kuala Lumpur Malaysia Abstract Muslim scholars during the Golden Age of Islamic history are known to have a great interest and respect in all kinds of knowledge especially knowledge related to applied science and technology; which can be useful in satisfying the needs of mankind. The developments of science and technology especially in engineering and medicine were actually available before the 14th century. However, historically, Muslim contributions towards science and technology have been neglected, ignored and to make it worse these contributions were attributed to other scholars and researchers. Keywords: Pulmonary circulation, Ibn Al-Nafis, Parkinson‟s disease, IbnRushd, Smallpox, Al-Razi, Flying machine, IbnFirnas. 1. Introduction This research investigates Muslim scholars‟ contributions during the Medieval Age. The main objective of this research is to identify the Muslim scholars‟ contributions which are attributed to other scholars especially in the fields of engineering and medicine. The significance of this research is to reveal the effort done by the Muslim scholars in science and technology. The methodology used in doing this research is library based as well as internet based research and most of the data are collected from accurate and reliable sources such as academic papers, journals and books. In this paper we select several important issues and finds in science and technology which attributed to other scholars. 2.
    [Show full text]
  • A Shelflist of Islamic Medical Manuscripts at the National Library of Medicine
    A Shelflist of Islamic Medical Manuscripts at the National Library of Medicine U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service | National Institutes of Health History of Medicine Division | National Library of Medicine Bethesda, Maryland 1996 Single copies of this booklet are available without charge by writing: Chief, History of Medicine Division National Library of Medicine 8600 Rockville Pike Bethesda, MD 20894 A Shelflist of Islamic Medical Manuscripts at the National Library of Medicine U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service | National Institutes of Health History of Medicine Division | National Library of Medicine Bethesda, Maryland 1996 Preface In 1994, to celebrate the 900th anniversary of the oldest Arabic medical manuscript in its collection, the History of Medicine Division of the National Library of Medicine mounted an exhibit entitled "Islamic Culture and the Medical Arts." Showcasing the library's rich holdings in this area, the exhibit was very well received -so much so that there has been a scholarly demand for the library to issue a catalogue of its holdings. This shelflist serves as an interim guide to the collection. It was made possible by the splendid work of Emilie Savage-Smith of Oxford University. Over the past few years, Dr. Savage-Smith has lent her time and her considerable expertise to the cataloguing of these manuscripts, examining every volume, providing much new information on authorship, contents, provenance, etc., superseding the earlier cataloguing by Francis E. Sommer, originally published in Dorothy M. Schullian and Francis E. Sommer, A Catalogue of Incunabula and Manuscripts in the Army Medical Library in 1950.
    [Show full text]